SALT LAKE CITY--(BUSINESS WIRE)--Jan 12, 2026--
Attorney Claine Snow has joined Dorsey & Whitney LLP as Of Counsel in the Patent group in Salt Lake City, the international law firm announced today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112525038/en/
Claine is a registered patent attorney with over a decade of experience serving companies in the pharmaceutical, chemical, biotech, and life sciences space. Prior to joining Dorsey, Claine was Executive Counsel at Arcturus Therapeutics, an RNA medicines company based in San Diego, CA. Claine’s role involved intellectual property strategy development and portfolio management for the company’s extensive patent estate, helping the company as it developed from a preclinical stage through multiple clinical trials and finally to its first product approval. Claine hopes to leverage his rich background as an in-house attorney combined with elite law firm training to make a valuable addition to Dorsey and Whitney’s brand.
Claine received his J.D. from Stanford Law School, his Ph.D. in Chemistry from Brigham Young University, and his B.S. in Chemistry from Brigham Young University, Idaho.
“We are delighted to welcome Claine to our Patent team,” said Matt Bethards, Business Group Head covering the Patent, Trademark, Copyright + Advertising Practice Groups. “With a Ph.D. in chemistry, Claine draws from a strong scientific background to help our life science and chemical technology clients navigate the intellectual property landscape and secure their valuable inventions.”
“Dorsey’s Patent group is renowned for its decades-long track record of leveraging deep technical and industry insights to safeguard client assets,” said Claine Snow. “I am eager to contribute to this distinguished team and provide top-tier service to our clients.”
About Dorsey & Whitney LLP
Clients have relied on Dorsey as a valued business partner since 1912. With locations across the United States and in Canada, Europe, and the Asia-Pacific region, Dorsey provides results-oriented, grounded counsel for its clients' legal and business needs. Dorsey represents a number of the world's most successful companies from a wide range of industries, including banking & financial institutions; development & infrastructure; energy & natural resources; food, beverage & agribusiness; healthcare & life sciences; and technology.
Attorney Claine Snow joined Dorsey & Whitney LLP as Of Counsel in the Patent group in Salt Lake City.
CUYAHOGA FALLS, Ohio--(BUSINESS WIRE)--Jan 13, 2026--
As medical device manufacturers face mounting pressures to reduce environmental risk, improve traceability, and accelerate product development, Americhem is preparing to highlight a suite of new technologies that reflect these industry shifts at Pharmapack (Paris) and MD&M West (Anaheim) in early 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112893294/en/
The company, known for its healthcare-focused polymer compounds and masterbatches, will showcase five key technologies, each designed to respond to the technical and regulatory complexities facing modern medtech—particularly in areas like connected care, self-administered delivery, and robotic-assisted interventions. Among the engineered solutions:
Americhem is actively engaging with OEM partners to co-develop and validate them for next-generation device applications. The company reports continued double-digit growth in its healthcare segment, supported by its ISO 13485-certified facilities in the U.S. and Denmark and upcoming expansion into China in 2026.
Americhem will also participate in the SPE Minitec Conference held during MD&M West, joining technical discussions on materials innovation for evolving care models.
“There’s a clear shift happening—material choices are now deeply tied to sustainability goals, regulatory scrutiny, and device functionality,” said Matt Miklos, Vice President of Corporate Strategy and M&A at Americhem. “What we’re bringing to these shows is not a catalog—it’s a pipeline of engineered solutions designed to be customized, scaled, and validated in partnership with OEMs who are navigating that complexity every day.”
Americhem’s approach emphasizes long-term material consistency, global compliance, and early design collaboration—factors increasingly prioritized by engineering and R&D teams charged with building the next wave of medical devices.
For technical inquiries or to request early access to sample materials, visit www.americhem.com/industries/healthcare/.
About Americhem
Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world. Visit www.Americhem.com for more information.
Engineered for medical nonwovens, Americhem’s PFAS-free nDryve™ additive delivers fluorine-free fluid repellency to surgical gowns, hygiene drapes, and barrier fabrics—addressing OEM demand for safer, sustainable performance in single-use healthcare textiles.
Americhem’s laser-marking ready thermoplastics enable permanent, high-contrast part identification directly on molded medical components—ideal for cleanroom environments where labels or inks are not viable. Designed for compliance and traceability, these materials support regulatory and workflow demands in modern device manufacturing.
